RT Journal Article
SR Electronic
T1 Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.28.21257611
DO 10.1101/2021.05.28.21257611
A1 Mueller, Tanja
A1 Laskey, Jennifer
A1 Baillie, Kelly
A1 Clarke, Julie
A1 Crearie, Christine
A1 Kavanagh, Kimberley
A1 Graham, Janet
A1 Graham, Kathryn
A1 Waterson, Ashita
A1 Jones, Robert
A1 Kurdi, Amanj
A1 Morrison, David
A1 Bennie, Marion
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.05.28.21257611.abstract
AB Objectives To discuss the opportunities and challenges when applying an electronic record linkage methodology with respect to systemic anti-cancer therapy, and to highlight some of the potential pitfalls spanning the entire breadth and depth of the research process.Design Retrospective cohort studies using routinely collected, administrative health data. Setting: ScotlandResults Studies conducted to-date have indicated that record linkage of routinely collected data to determine outcomes of treatment with cancer medicines is feasible, albeit currently within certain limits. While the general description of patient populations and the calculation of median overall survival are well supported, prevailing issues with combining data across regional boundaries and the limited availability of some variables (including molecular pathology data and information regarding toxicities) may restrict the extent of analyses feasible.Conclusion There is scope to conduct large cohort studies to generate results from clinical practice using linkage of routinely collected health care data within a reasonable time frame; however, close collaboration between researchers, data controllers, and clinicians is required in order to obtain valid and meaningful results.Strengths and limitations of this studyThis is the first description of a comprehensive programme aimed at evaluating the feasibility of linking routinely collected health data to evaluate the outcomes of systemic anti-cancer treatment in clinical practice.The multi-disciplinary study team comprised both academics and clinicians, with a wide range of skills, expertise, and experience.While a number of studies focusing on different cancers have successfully been conducted, not all research questions of interest could be fully answered due to some existing data gaps.Nevertheless, study findings have been discussed with health care professionals across Scotland, and have started to have an impact on shared patient-clinical decision making.Competing Interest StatementKB is currently attending the 2019-2021 PM Clinical Leadership in Pharmacy in Scotland programme, which is sponsored by Daiichi Sankyo UK, GlaxoSmithKline, and Napp Pharmaceuticals. RJ has received grants, personal fess and non-financial support from Bayer; grants and personal fees from Astellas, Astra Zeneca, Exelixis, Roche; personal fees and non-financial support from Bristol Myers Squibb, Janssen, Ipsen, MSD; personal fees from Merck Serono, Novartis, Pfizer, Sanofi Genzyme, EUSA; outside the submitted work. JL, KB, JC, CC, JG, KG, AW, DM and MB are employees of the National Health Services Scotland/Public Health Scotland. TM, KK and AK have no competing interests.Funding StatementThis work was supported by the Scottish Government. The funder has no role in the study design, data collection, data analyses, or interpretation of data; or in the preparation or review of manuscripts for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of NHS data was approved by the local Caldicott Guardian (NHS Greater Glasgow & Clyde) and/or the Public Benefit and Privacy Panel for Health and Social Care (study numbers 1617-0371/1917-0371; 1819-0055). In addition, accessing data was approved by the NHS Greater Glasgow & Clyde Safe Haven (study numbers GSH/17/ON/003; GSH/18/ON/012; GSH/19/ON/002); permissions include ethical approval (REC numbers for devolved rights to approve projects: 12/WS/0142; 17/WS/0237). All studies have been conducted in accordance with information governance standards; no identifiable data was available to researchers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNHS data is confidential, and is only available upon request subject to approval by a Caldicott Guardian/the Public Benefit and Privacy Panel for Health and Social Care.